SubsidieMeestersThe first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika
ATLAS aims to develop the first broad-spectrum antiviral for flavivirus infections, conducting Phase I and IIa trials for dengue to attract pharmaceutical partnerships for commercialization.
Projectdetails
Introduction
WHO, governments, and health institutes are urgently seeking methods to prevent future catastrophic flavivirus outbreaks affecting millions. Annually, over 40% of the global population is at risk, resulting in approximately 395 million infections, more than 25,000 deaths (mainly children), 750,000 disability-adjusted life years, and over €9 billion in direct and indirect costs.
Project Overview
As there are no effective treatments or vaccines available, ATLAS will provide a breakthrough in broad-spectrum antivirals: the first-in-class drug to combat the global health emergency of flaviviral infections.
Objectives
In the ATLAS project, Protinhi will:
- Finalize clinical trial-enabling studies.
- Conduct pharmaceutical development.
- Obtain proof-of-concept in humans by conducting Phase I and Phase IIa clinical trials against the most common flavivirus: dengue.
Strategic Partnerships
This will put the company in an excellent position to attract interest from pharmaceutical companies (e.g., Gilead, J&J, MSD) for a strategic partnership for late clinical development and commercialization.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 14.465.988 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-8-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PROTINHI BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Fighting Large-Scale Untreated Infectious Diseases with Innovative TreatmentsMeletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Mosquito-specific phagostimulants and pheromones for environment-friendly mosquito vector controlMolecular Attraction aims to evaluate the efficacy and environmental impact of innovative mosquito-specific semiochemicals in sub-Saharan Africa to enhance vector control and reduce disease burden. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments
Meletios is developing a broad-spectrum oral antiviral that targets cell mechanisms to treat acute viral infections, starting with COVID-19, while also managing immune responses.
Mosquito-specific phagostimulants and pheromones for environment-friendly mosquito vector control
Molecular Attraction aims to evaluate the efficacy and environmental impact of innovative mosquito-specific semiochemicals in sub-Saharan Africa to enhance vector control and reduce disease burden.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Protini pan-Corona antiviralsProtinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden. | Mkb-innovati... | € 20.000 | 2020 | Details |
THERAPRODit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen. | Mkb-innovati... | € 163.275 | 2019 | Details |
Universal building blocks for antigen presentation to uncover the flavivirus-directed antibody responseThe FLAVIR project aims to develop a structural proteomics toolkit using mass spectrometry and electron microscopy to enhance understanding of neutralizing antibody responses against flaviviruses for vaccine development. | ERC Starting... | € 1.687.500 | 2023 | Details |
Mobile Bio-Lab to support first response in Arbovirus outbreaksMOBVEC aims to develop the first VBD Mobile Bio-Lab to provide real-time vector surveillance and disease modeling, enhancing outbreak response and saving lives and healthcare costs. | EIC Pathfinder | € 2.998.500 | 2023 | Details |
Vector Control CapsulesHet project richt zich op het bestrijden van de Aedes aegypti mug om de verspreiding van virussen zoals dengue en Zika te verminderen en zo de wereldwijde gezondheidsrisico's te verlagen. | Mkb-innovati... | € 185.003 | 2017 | Details |
Protini pan-Corona antivirals
Protinhi onderzoekt stoffen uit een bibliotheek voor behandelingen tegen dengue en Zika, met potentieel voor COVID-19, om patenten te ondersteunen en partners voor vervolgfinanciering te vinden.
THERAPRO
Dit project richt zich op het ontwikkelen van een behandeling voor West-Nile- en Chikungunya-virusinfecties door innovatieve screening van stoffen, om de virusvermenigvuldiging te stoppen.
Universal building blocks for antigen presentation to uncover the flavivirus-directed antibody response
The FLAVIR project aims to develop a structural proteomics toolkit using mass spectrometry and electron microscopy to enhance understanding of neutralizing antibody responses against flaviviruses for vaccine development.
Mobile Bio-Lab to support first response in Arbovirus outbreaks
MOBVEC aims to develop the first VBD Mobile Bio-Lab to provide real-time vector surveillance and disease modeling, enhancing outbreak response and saving lives and healthcare costs.
Vector Control Capsules
Het project richt zich op het bestrijden van de Aedes aegypti mug om de verspreiding van virussen zoals dengue en Zika te verminderen en zo de wereldwijde gezondheidsrisico's te verlagen.